Guard Therapeutics International AB (publ)

Stockholm Stock Exchange GUARD.ST

Guard Therapeutics International AB (publ) Gross Profit Margin for the year ending December 31, 2023

Guard Therapeutics International AB (publ) Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Stockholm Stock Exchange: GUARD.ST

Guard Therapeutics International AB (publ)

CEO	Mr. Tobias Larsson Agervald
IPO Date	April 3, 2013
Location	Sweden
Headquarters	Nybrogatan 34, 2 tr
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Key trends

Past 5 years